Dengue and leishmaniasis, high priorities in Brazil:
This article was originally published in Clinica
The diagnosis of Dengue fever and leishmaniasis remain high priorities of the Brazilian health ministry. The national healthcare foundation - Fundacao Nacional de Saude (Funasa) - has announced that it is continuing to train healthcare surveillance personnel specialised in these two mosquito-borne viral diseases. The last several months have seen the worst dengue epidemic in recorded history (see Clinica No 1001, p 14). In January 2002 alone, Funasa trained around 89,000 dengue surveillance agents, in a bid to improve early detection and treatment of the disease. Leishmaniasis is currently present in 19 states, with 90% of cases reported in the Northwest region.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.